Mapping Biology at Scale

In this episode of The Quantum Leap, Dr. Nirdosh Jagota explores a fundamental shift in drug discovery—from traditional target-based approaches to a data-first, phenotypic discovery model powered by artificial intelligence. He examines how companies like Recursion Pharmaceuticals are redefining the scientific method by moving beyond human hypothesis and allowing large-scale biological data to guide discovery.

Dr. Jagota details how Recursion’s platform leverages high-throughput robotics, advanced imaging, and machine learning to generate massive datasets—capturing millions of cellular experiments each week. These datasets form a continuously evolving “cellular atlas,” enabling AI systems to uncover complex biological relationships that are often invisible to human researchers.

The episode highlights the transition from intuition-driven science to computational mapping of biology, where phenotypic screening identifies therapeutic opportunities based on observable cellular outcomes rather than predefined targets. Dr. Jagota also discusses Recursion’s strategic collaborations with industry leaders such as Roche, Bayer, and NVIDIA, as well as its merger with Exscientia—creating a powerful, integrated AI-driven drug discovery ecosystem.

With multiple clinical-stage programs underway, this episode demonstrates how scaling biology through AI is transforming drug discovery into a systematic, data-driven discipline, accelerating the path from discovery to patient impact.

For deeper insights into AI-driven life sciences and Dr. Jagota’s expert perspectives, please visit: 🌐 https://nirdoshjagota.us/

🌐 https://nirdoshjagota.net/

🌐 https://nirdoshjagota.com/

🌐 https://aboutnirdoshjagota.com/